what is known already: Uterine leiomyoma, the benign smooth muscle cell tumor, is the single most common indication for hysterectomy. High expression of MMPs or TNF-a has been reported in uterine leiomyomas; however, the molecular mechanism underlying these observations remains unknown. participants/materials, setting, methods: Western blot, RT -qPCR and a wound-healing assay were used to investigate the effects of TNF-a on MMP-2 expression and intracellular signal transduction in cultured SMCs from leiomyomas and matched myometrium.
Introduction
Uterine leiomyoma, the most common gynecologic neoplasm, occurs in .70% of reproductive-age women (Lumsden and Wallace, 1998; Rein, 2000; Flake et al., 2003) . Steroid hormones are believed to play critical roles in the pathogenesis of the tumor (Burroughs et al., 2000; Di et al., 2008) ; however, despite much investigation, including genetic and molecular approaches, the underlying mechanism of uterine leiomyoma remains unclear.
Tumor necrosis factor-a (TNF-a) is a pleiotropic cytokine involved in inflammation, immunity, migration, cellular homeostasis and tumor progression (Balkwill, 2009) . Several investigators have shown that the abundance of TNF-a is regulated by steroid hormone levels. Indeed, TNF-a levels dropped in ovariectomized mice, whereas the administration of estradiol and progesterone resulted in the reappearance of this cytokine (Roby and Hunt, 1994) . The expression of TNF-a in uterine leiomyoma was higher than that in the adjacent myometrium and was significantly down-regulated by addition of progesterone (Kurachi et al., 2001) . Although, some evidence has suggested a role for TNF-a in the pathogenesis of uterine leiomyoma, details on the TNF-a-mediated signaling pathways in leiomyoma smooth muscle cells (SMCs), such as downstream adaptor proteins or phosphorylation steps, are still largely unknown.
Tissue remodeling involving 'extracellular matrix (ECM) turnover' plays a key role in leiomyoma growth and is regulated by the combined actions of matrix metallo-proteinases (MMPs), a family of .20 zincdependent endopeptidases (Islam et al., 2013) . Previous studies have shown that several forms of MMPs are expressed in myometrium and leiomyomas (Dou et al., 1997; Bodner-Adler et al., 2004; Wolańska et al., 2004; Bogusiewicz et al., 2007) . Moreover, the activity of MMP-2 is higher in human leiomyoma tissues compared with normal myometrium (Inagaki et al., 2003) . In vitro studies have shown that cytokines such as TNF-a and interleukin-1b increase the expression and activity of MMP-2 in vascular SMCs (Galis et al., 1994; Fabunmi et al., 1996) , which serves as a stimulus for us to examine whether TNF-a has different effects on MMP-2 expression in myometrial and leiomyoma SMCs.
The present study was designed to characterize the effects of TNF-a on MMP-2 expression and intracellular signaling pathways in primary cultured SMCs obtained from human leiomyomas and matched myometrium. Our study was expected to establish a potential role for TNF-a/MMP-2 in the pathogenesis of uterine leiomyoma.
Materials and Methods

Antibodies
Antibodies against phospho-p44/42 (ERK) MAPK (Thr202/Tyr204), total p44/42 (ERK) MAPK, phospho-ELK-1, phospho-IkBa (Ser32/36) and total IkBa (L35A5) were obtained from Cell Signaling (Beverly, MA, USA).
The MMP-2 and MMP-9 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and the b-actin antibody was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Tissue collection
Uterine leiomyoma and matched normal myometrial tissues were obtained from patients (35-50 years old) undergoing a hysterectomy at the Central Hospital for Obstetrics and Gynecology, Tianjin, People's Republic of China. Premenopausal patients who underwent a hysterectomy without concurrent unilateral or bilateral adnexectomy due to benign uterine disorders were enrolled in this study. The Ethical Review Board of Tianjin Central Hospital for Obstetrics and Gynecology approved this study and all participants gave written informed consent. All of the included patients had ovulatory cycles. The endometrium of those patients was in the proliferative phase, which was diagnosed by pathologists in the Pathology Department of Tianjin Central Hospital for Obstetrics and Gynecology using dilation and curettage (D&C). The tumor size ranged from 3 to 12 cm in diameter. None of the patients was administered any medication or hormonal therapy for at least 3 months prior to surgery. Samples were excluded from the study if accurate menstrual cycle dates could not be assigned or if unexpected pathology was found (e.g. endometriosis or other pelvic inflammatory diseases). Samples with evidence of adenomyosis were excluded, which was specifically examined by a pathologist. All tissue samples used for this study were confirmed as histologically ordinary leiomyomas, with no cellular, epithelioid, unusual or plexiform variants present. After surgery, some tissues were collected and stored in liquid nitrogen for the extraction of protein and RNA for western blot and RTqPCR analyses, respectively. Another fraction of fresh tissues was used for primary cell culture, as previously described Tian et al., 2013) .
Primary cell culture
Human leiomyoma (HL) and matched myometrium (HM) SMCs were isolated from uterine leiomyoma and normal myometrial tissues, respectively. Uterine leiomyoma and matched myometrial tissues from the same patient were cut into small pieces ( 1 mm 3 ) and placed into dissociation solution [Dulbecco's modified Eagle's medium (DMEM), 20% v/v fetal bovine serum (FBS), 0.2% v/v collagenase II (Invitrogen, Carlsbad, CA, USA) and 50 mg/ml trypsin inhibitor (Sigma-Aldrich)], followed by incubation for 2 -6 h at 378C, with the dissociation solution changed every 2 h. The dissociated tissues were filtered through a sterile 100-mm mesh filter, and the isolated cells were washed three times with phosphate-buffered saline (PBS) using 400 g centrifugation for 5 min. Cells were resuspended in phenol red-free DMEM (Hyclone, Logan, UT, USA) with 10% v/v heat-inactivated FBS (Hyclone) and 1% v/v antibiotic solution (Sigma-Aldrich) for further culture. The cultures were maintained in a standard 95% air, 5% CO 2 incubator at 378C. When 95-100% cell confluence was reached, cells were passaged by the standard method of trypsinization, plated in culture dishes and grown in phenol red-free DMEM supplemented with 10% FBS. Cells from passages three to five were used for all the experiments. Monolayer HM-and HL-SMCs were rendered quiescent by incubation in phenol red-free DMEM containing no FBS for 24 h. The cells were then used to test the effect of human recombinant TNF-a (Sigma-Aldrich) on the expression of MMP-2 and 9 protein and mRNA. The following inhibitors were added to the cells 30 min before treatment with 10 ng/ml TNF-a for 24 h at 378C: 10 mM PD98059 (Sigma-Aldrich), 25 mM Bay11-7082 (Santa Cruz, CA, USA) or 5 mM U0126 (Sigma-Aldrich). All treatments were performed in phenol red-free media containing no FBS. Each experiment was performed in triplicate.
Western blot
Tissues and cultured SMCs were lysed with ice-cold lysis buffer [150 mM NaCl, 50 mM Tris-Cl (pH 7.5), 1 mM EDTA, 1% v/v NP-40, 0.1% v/v sodium dodecyl sulfate, 0.25% v/v sodium deoxycholate, 1 mM phenylmethylsulphonyl fluoride, 1 mM b-glycerophosphate, 1 mM NaF, 1 mM Na 3 VO 4 and protease inhibitor cocktail tablets (Roche Molecular BioChemicals, Indianapolis, IN, USA)], followed by centrifugation at 48C for 10 min (1000 g). Protein concentrations were determined using a bicinchoninic acid (BCA) Protein Assay Reagent (Pierce, Rockford, IL, USA) according to the manufacturer's instructions. Aliquots containing 25-40 mg of protein were mixed with loading buffer, followed by denaturation at 958C for 5 min. Proteins were separated by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes. The membranes were blocked with 5% v/v nonfat milk in Tris-buffered Saline/Tween-20 (TBST) buffer (20 mM Tris-HCl, pH 7.6, 136 mM NaCl and 0.1% v/v Tween-20) and then probed for 1.5 h or overnight with primary antibodies: MMP-2, 1:500; MMP-9, 1:500; b-actin, 1:5000. The membranes were then incubated with horseradish peroxidase-conjugated secondary antibody (dilution: 1:5000) for 1.5 h at room temperature. Protein signals were visualized using the West Pico Chemiluminescent Substrate Kit (Pierce) . Images were acquired by a Molecular Image Chemidoc XRS System and analyzed using Quantity One software (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
ERK activity assay
The ERK activity assay was performed as we previously described . Twenty micrograms of protein was incubated with 15 ml immobilized phospho-ERK1/ERK2 antibody with gentle rocking at 48C overnight. The immunocomplex was then incubated with 50 ml kinase buffer containing 200 mmol/l ATP and 2 mg Ets-like protein 1(ELK-1) at 308C for 30 min, followed by western blot analysis with phospho-ELK-1 antibody.
Reverse transcription and real-time quantitative polymerase chain reaction
Total RNA in tissues or cultured cells was extracted using an RNeasy Mini Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer's instructions. RNA concentrations were determined from the absorbance at 260 nm and corrected for protein contamination by the ratio of the absorbances at 260 and 280 nm (A260/280). Reverse transcription was performed using 1 mg of total RNA in a 25-ml reaction volume at 428C for 60 min using a PCR machine (Hangzhou Jingle Scientific Instrument CO. Ltd., Hangzhou, China). All qPCR experiments were performed on a real-time PCR machine (Bio-Rad Laboratories) with the QuantiTect SYBR Green PCR Kit and gene-specific primers purchased from QIAGEN. Gene expression was quantified by the comparative cycle threshold (Ct) method. The relative amounts of target gene mRNA were determined by subtracting the Ct values for these genes from the Ct value for the housekeeping gene b-actin (△Ct). The data are presented as 2 2△Ct .
Immunohistochemistry
Formalin-fixed, paraffin-embedded samples of uterine leiomyoma and matched myometrial tissues were cut into 4 mm sections. After deparaffinization, slides were boiled in citrate buffer (10 mM, pH 6.0) for 15 min for antigen retrieval. Sections were then immersed in 3% v/v hydrogen peroxide for 20 min to block endogenous peroxidase. Afterwards, slides were incubated in a humidified chamber with 5% v/v blocking goat serum in Tris-buffered Saline (TBS) for 30 min at room temperature. The excess serum was drained and sections were incubated with primary MMP-2 antibody (1:100; Santa Cruz, CA, USA) overnight at 48C. Non-immune (normal) immunoglobulin G was used at the same concentration as the primary antibody for negative control. After being washed three times for 5 min with TBS, biotinylated goat anti-rabbit antibody (1:1000; Abcam, Cambridge, MA, USA) was added as secondary antibody for 40 min at room temperature. The antigen-antibody complex was detected using an avidin-biotin-peroxidase kit (Vector Laboratories, Burlingame, CA, USA). Diaminobenzidine (Vector Laboratories) was used as the chromogen and sections were counterstained with hematoxylin.
Wound-healing assay
The cultured human leiomyoma SMCs (passages three to five) were seeded in six-well plates. When 70% cell confluence was reached, the leiomyoma SMCs were rendered quiescent by incubation for 24 h in phenol red-free media containing no fetal bovine serum. Confluent monolayer cells were scratched in a straight line with a p200 pipet tip; the cell debris and suspended cells were removed by washing the cells with serum-free DMEM. The cells were then incubated in serum-free DMEM, and pretreated with or without PD98059 (10 mM) for 30 min in the absence and presence of TNF-a (10 ng/ml). After 24 h of incubation at 378C, additional images were then captured by aligning the dishes with the reference point made at 0 h. The distance between one side of the scratch and the other was measured using Image Pro-Plus software (Media Cybernetics, Inc., Warrendale, PA, USA). Cell migration was indicated as wound exposure and expressed as percentage of unhealed distance of treated cells versus that of control cells.
Statistical analysis
The data were presented as the means with the 95% confidence intervals (CIs) (n ¼ replicate number of experiments). The normality of the data distributions was first assessed using the Kolmogorov-Smirnov test. Differences were analyzed with a two-tailed paired t-test or one-way ANOVA followed by the Newman -Keuls post hoc test as appropriate. The statistical analysis was performed using Instat 3.0 (GraphPad Software, San Diego, CA, USA), and P , 0.05 was considered statistically significant.
Results
MMP-2 expression is up-regulated in human uterine leiomyoma
Uterine leiomyomas and their matched myometrial tissues were sampled for protein and mRNA for western blot (n ¼ 12) and RT-qPCR (n ¼ 12) analyses, respectively. Western blot analysis showed that the levels of MMP-2 protein in leiomyoma tissues were significantly higher compared with the matched myometrium tissues (P ¼ 0.008; Fig. 1A and B). Consistently, as shown in Fig. 1C , the levels of mmp-2 mRNA from these patients were significantly higher in leiomyoma tissues than their matched myometrium tissues (P ¼ 0.009), suggesting up-regulation of mmp-2 gene expression in uterine leiomyomas. Immunohistochemistry was performed to confirm this finding. As shown in Fig. 1D , MMP-2 signals appeared outside the nuclei and were much stronger in uterine leiomyoma than that in matched normal myometrium or adjacent myometrium.
ERK activity is down-regulated in human uterine leiomyoma
We proceeded to examine the activity of the ERK pathway in uterine leiomyomas and their matched myometrial tissues. As described
Tumor necrosis factor-a and uterine leiomyoma in our previous study , leiomyoma tissues (n ¼ 12) have significantly lower levels of phospho-ERK1/ERK2 than myometrium tissues, but the total ERK1/ERK2 levels were similar in both tissues (Fig. 1E ), suggesting suppression of the ERK pathway. This result was further confirmed with kinase activity assay (Fig. 1F) . 
TNF-a increases the expression of MMP-2 in HL-SMCs but not in HM-SMCs
To investigate whether the high expression of MMP-2 in uterine leiomyoma tissues is related to the presence of TNF-a, we established primary culture of SMCs from uterine leiomyoma and matched myometrial tissues. Both the myometrium and leiomyoma SMCs stained positive for the smooth muscle marker proteins ( Supplementary Fig. S1A ), as described in our previous study . Western blot results showed less calponin and SM a-actin present in leiomyoma SMCs (n ¼ 3) (Supplementary Fig. S1B ). The basal expression levels of MMP-2 were then evaluated in cultured HM-and HL-SMCs using western blot and RT -qPCR analyses. Our results showed that MMP-2 protein (n ¼ 5; P ¼ 0.006) and mRNA expression (n ¼ 5; P ¼ 0.002) in HL-SMCs was much higher than that in HM-SMCs ( Fig. 2A and B) . Subsequently, we examined the effects of various concentrations of TNF-a on MMP-2 expression in both SMCs types. As shown in Fig. 2C , treatment with TNF-a for 24 h concentration-dependently Figure 2 Tumor necrosis factor-a (TNF-a) increases matrix metalloproteinase-2 (MMP-2) expression in human leiomyoma smooth muscle cells (HL-SMCs). Primary cell culture of SMCs from myometrium and matched uterine leiomyoma was performed using the enzyme digestion approach. Protein and total RNA were extracted from cells in passages three to five for western blot and RT -qPCR analyses, respectively. Tumor necrosis factor-a and uterine leiomyoma stimulated the expression of MMP-2 mRNA (P ¼ 0.012) in cultured leiomyoma SMCs (n ¼ 3), but not in the myometrium SMCs (n ¼ 3). Treatment with 10 ng/ml TNF-a for 48 h in HL-SMCs (n ¼ 3) maintained the significantly up-regulated expression of mmp-2 mRNA (P ¼ 0.037) and protein (P ¼ 0.039; Fig. 2D-F) .
Because matrix metalloproteinase-9 (MMP-9) and MMP-2 have similar specificities towards the substrates, we also detected the effects of TNF-a on the expression of MMP-9 using RT-qPCR and western blot analyses. Conversely, treatment with 10 ng/ml TNF-a did not affect the MMP-9 protein expression in leiomyoma SMCs, but time-dependently increased the MMP-9 mRNA expression (data not shown).
TNF-a activates the ERK pathway in HL-SMCs
Because leiomyoma tissues have significantly lower levels of phosphp-ERK1/ERK2 than myometrium tissues ( Fig. 1E and F) , we examined the effects of TNF-a on ERK1/ERK2 phosphorylation in primary cultured HL-and HM-SMCs. As shown in Fig. 3A , 10 ng/ml TNF-a treatment reduced the level of phospho-ERK1/ERK2 in HM-SMCs (n ¼ 4) but increased the ratio of phospho-ERK1/ERK2 and total ERK1/ERK2 in HL-SMCs (n ¼ 4) as early as 5 min (P ¼ 0.032), reaching a peak at 15 min (P ¼ 0.006). Pretreatment with PD98059 (10 mM, 30 min), a specific MEK inhibitor, suppressed the ERK1/ERK2 phosphorylation induced by TNF-a in HL-SMCs (Fig. 3B) .
Having shown that the ERK signaling pathway is activated by TNF-a in HL-SMCs, we addressed whether ERK1/ERK2 phosphorylation is required for TNF-a-induced MMP-2 expression. Pretreatment of HL-SMCs (n ¼ 4) with PD98059 (10 mM) abolished TNF-a-induced MMP-2 expression at both protein ( Fig. 3C and D) and mRNA levels (Fig. 3E) , as detected by western blot and RT-qPCR, respectively. Consistently, U0126 (5 mM), a mechanistically different inhibitor of ERK activation, also inhibited the levels of MMP-2 mRNA and protein up-regulated by TNF-a in HL-SMCs (data not shown).
TNF-a activates the nuclear factor-kappa B (NF-kB) pathway in HL-SMCs
To investigate whether the transcription factor NF-kB is also stimulated by TNF-a in leiomyoma SMCs through the canonical pathway, we evaluated the phosphorylation of cytoplasmic inhibitor IkBa using western blot analysis. Our results revealed that IkBa was transiently phosphorylated as early as 5 min (P ¼ 0.04) after treatment with 10 ng/ml TNF-a, reaching a peak at 60 min (P ¼ 0.008) in HL-SMCs (n ¼ 3); however, TNF-a did not induce IkBa phosphorylation in HM-SMCs (n ¼ 3) (Fig. 4A) . To explore whether IkBa is phosphorylated through the ERK pathway, we examined IkBa phosphorylation by pretreatment with PD98059 (10 mM, 30 min). As shown in Fig. 4B , PD98059 was able to inhibit TNF-a-activated IkBa phosphorylation, demonstrating the ERK dependence of IkBa phosphorylation in HL-SMCs. Moreover, pretreatment of HL-SMCs with Bay 11-7082 (Pierce et al., 1997) , an IkBa phosphorylation inhibitor (25 mM, 30 min), suppressed the IkBa phosphorylation induced by TNF-a, as determined by western blot.
We also examined whether IkBa phosphorylation is required for TNF-a-induced MMP-2 expression. As shown in Fig. 4C and D, pretreatment of HL-SMCs (n ¼ 3) with Bay11-7082 (25 mM) inhibited TNF-a-induced MMP-2 expression at both protein and mRNA levels, as detected by western blot and RT -qPCR, respectively. Therefore, it is concluded that the NF-kB signaling pathway is also involved in the up-regulation of MMP-2 induced by TNF-a in cultured leiomyoma SMCs.
TNF-a promotes the migration of HL-SMCs
It is generally accepted that MMPs are important for vascular SMC migration into the intima (Suh et al., 2012) . Because TNF-a induced MMP-2 expression in cultured leiomyoma SMCs, we investigated whether TNF-a promotes cell migration of HL-SMCs with an in vitro woundhealing study. As shown in Fig. 5A and B, TNF-a treatment of Figure 4 Tumor necrosis factor-a (TNF-a) activates the nuclear factor-kappa B (NF-kB) pathway in human leiomyoma smooth muscle cells (HL-SMCs). (A) Cumulative western blots showing the phosphorylation of ikBa in HL-and matched HM-SMCs treated with or without TNF-a for different times. Inserts: Representative western blot results showing the phosphorylation of ikBa in HL-and HM-SMCs. The y-axis represents the proportion of total ikBa phosphorylated relative to t0 (*P , 0.05 versus cells at t0, n ¼ 3). (B) Cumulative western blots showing the phosphorylation of ikBa in HL-SMCs treated with or without TNF-a (10 ng/ml), PD98059 (10 mM) and Bay11-7082 (25 mM). The y-axis represents the proportion of total ikBa that is phosphorylated relative to control (*P , 0.05 versus control cells, n ¼ 3). (C) Representative western blots of MMP-2 and b-actin. (D) Cumulative western blot results showing the expression of MMP-2 in HL-SMCs treated with or without TNF-a (10 ng/ml) and Bay11-7082 (25 mM). The y-axis represents MMP-2 protein expression relative to control (*P , 0.05 versus control cells, n ¼ 3). (E) RT -qPCR data showing the mRNA levels of mmp-2 in HL-SMCs treated with or without TNF-a (10 ng/ml) and Bay11-7082 (25 mM). The y-axis represents MMP-2 mRNA expression relative to control (*P , 0.05 versus control cells, n ¼ 3). The data are presented as means with 95% confidence intervals (CIs).
Tumor necrosis factor-a and uterine leiomyoma HL-SMCs promoted cell migration compared with the control cells (n ¼ 5; P ¼ 0.038), which might be due to the increased expression of MMP-2. Moreover, pretreatment with PD98059, the ERK specific inhibitor, greatly compromised this cell migration effect, possibly via the inhibition of MMP-2 expression.
Discussion
To the best of our knowledge, this is the first report showing that TNF-a regulates the ERK and NF-kB pathways differently in SMCs from leiomyoma and matched myometrium, in particular promoting the migration of cultured leiomyoma SMCs (Fig. 5C) . Stimulation of MMP-2 expression by TNF-a in leiomyoma SMCs suggests a role for TNF-a in the overexpression of MMP-2 in uterine leiomyoma tissues.
MMPs have long been associated with tumor progression by virtue of their ability to degrade all structural components of the ECM (Visse and Nagase, 2003) . In several cases, the stage of tumor progression has been positively correlated with the expression of MMP family members (Stetler-Stevenson, 1996) . Consistently, tumor growth and angiogenesis are reduced in MMP-2-knockout mice (Itoh et al., 1998) . Our results show high levels of MMP-2 in human uterine leiomyoma, further supporting a role for MMP-2 in tumor progression. Under normal physiological conditions, MMPs are tightly regulated at the transcriptional and posttranscriptional levels and are also controlled at the protein level via their activators, inhibitors and cell surface localization (Sternlicht and Werb, 2001) . Our in vitro studies also revealed that TNF-a treatment significantly up-regulates MMP-2 expression, suggesting that high MMP-2 expression in uterine leiomyoma tissues may result from TNF-a effects in vivo. Therefore, our data strongly indicate that the up-regulation of MMP-2 expression plays a potential role in the pathogenesis of human uterine leiomyoma. Since mice without MMP-2 are viable (Itoh et al., 1998) , it will be interesting to examine whether uterine leiomyoma develops in these animals.
The increased biosynthesis of TNF-a was reported in uterine leiomyoma tissues (Kurachi et al., 2001) , strongly suggesting a role for TNF-a in its pathogenesis. Therefore, our observation that TNF-a treatment increased mmp-2 gene expression in leiomyoma SMCs further supports a role for the up-regulation of mmp-2 gene expression in the development of uterine leiomyoma. Moreover, TNF-a-related cancers, such as breast cancer (Hagemann et al., 2004) and osteosarcoma (Nyormoi et al., 2003) , exhibited MMP-2 up-regulation, further supporting a role for up-regulated MMP-2 expression in tumor growth and the potential role of TNF-a in this up-regulation. The difference in TNF-a response existing between human leiomyoma tissue and their matched myometrium may be regulated by hormone levels. Hormones such as estrogen (E2) and progesterone (P4) are considered to be promoters of leiomyoma growth (Park et al., 2008; Ishikawa et al., 2010) . We did not assess the hormonal status of the patients included in our study; however, the underlying mechanism should be explored in the future investigations.
Notably, our previous study has shown that leiomyoma tissues have significantly lower levels of phospho-ERK1/ERK2 than myometrium tissues . Therefore, in cultured SMCs, we predicted that TNF-a may decrease the phosphorylation of ERK1/ERK2. Unexpectedly, our results showed that TNF-a increased the ERK1/ERK2 phosphorylation in leiomyoma SMCs. To date, there has been no explanation for these contradictory observations. However, there is no doubt that cells in tissue culture conditions may not behave in precisely the same way as in vivo due to the microenvironment of the cell.
NF-kB is one of the major transcription factors stimulated by TNF-a and plays a pivotal role in controlling the initiation and progression of cancer (Basseres and Baldwin, 2006) . Our results revealed that the NF-kB pathway is activated by TNF-a in leiomyoma SMCs, which contributes to the up-regulation of MMP-2 expression. Therefore, our results further support a role for MMP-2 up-regulation in tumor progression. A previous report has demonstrated that the Akt pathway is involved in regulating TNF-a-activated NF-kB in cardiac myocytes (Condorelli et al., 2002) . We observed that activation of the NF-kB pathway was effectively inhibited by PD98059, a specific inhibitor of ERK, suggesting a role for ERK in regulating NF-kB function in leiomyoma SMCs. However, as the precise function of NF-kB transcription factors on MMP-2 regulation is not clearly demonstrated in this study, further experiments are required using cell transfection to over-express constitutively active and/or mutated NF-kB constructs and/or deletion of the NF-kB binding site in the MMP-2 promoter.
Previous studies demonstrate that TNF-a is a potential migration factor for different cell types, such as fibroblasts and inflammatory cells (Furie and McHugh, 1989; Postlethwaite and Seyer, 1990) . However, several investigators have revealed that TNF-a specifically inhibits trophoblast migration and invasion (Bauer et al., 2004) . Although it is well known that the migration of vascular SMCs (VSMCs) is dependent on the ERK pathway activated by TNF-a, little is known about the effects of TNF-a on uterine leiomyoma SMC migration and the chemotactic signaling pathways mediating this action. Our results reveal that TNF-a stimulates the migration of HL-SMCs through the ERK signaling pathway. Using the ERK specific inhibitor PD98059, we are able to reveal that activation of the ERK pathway is a critical signaling step for TNF-a-induced leiomyoma SMC migration. On the other hand, we previously described that treatment with G-1, a G-protein-coupled receptor 30 (GPR30) agonist and epidermal growth factor (EGF) stimulated the phosphorylation of ERK in both SMC types Tian et al., 2013) ; however, these studies did not investigate whether the ERK pathway is involved in the migration of cultured leiomyoma SMCs. The migration of uterine leiomyoma SMCs has also been linked to other molecules, such as CCN5 and heparin, which inhibit the motility of both human myometrial and leiomyoma SMCs (Mason et al., 2003 (Mason et al., , 2004 .
MMPs directly modulate cell -matrix adhesion either by removal of sites of adhesion or by exposing a binding site, which can be translated into an effect on cell migration (McCawley and Matrisian, 2001) . It is generally accepted that MMP-2 and -9 are possibly involved in the migration potential of VSMCs (Suh et al., 2012) . The precise effect of MMP-2 on leiomyoma SMC migration is not demonstrated in this study, and further experiments may require the use of endogenous MMP inhibitors known as tissue inhibitor of metalloproteinases (TIMPs).
Taken together, our results reveal that MMP-2 is overexpressed in human uterine leiomyomas compared with the matched myometrium. TNF-a up-regulates the MMP-2 expression and promotes the migration of human leiomyoma SMCs via the ERK signaling pathway. Given the stimulatory effect of TNF-a on MMP-2 expression, we speculate that TNF-a may result in the up-regulation of MMP-2 in vivo, contributing to tumor growth. Considering the positive effect of TNF-a on leiomyoma SMC migration, strategies targeting TNF-a, in parallel with the production of more specific inhibitors of MMPs, may provide alternative therapeutic approaches for the treatment of leiomyoma.
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